| 초록 |
Type 2 diabetes mellitus is a disease that increases insulin resistance due to long-lasting hyperglycemia. FGF-21 is a protein mostly expressed in the liver and pancreas, which improves insulin resistance and reduces plasma levels of glucose. However, the therapeutic effect is limited because the half-life of FGF21 protein is about 2 hours. Here we designed orally active FGF-21 gene therapy. For this, we newly prepared chitosan-based gene carrier. The orally administered FGF-21 gene was absorbed into the intestine and circulated through the blood circulation system. we confirmed whether FGF-21 polyplex was penetrated through Caco-2 monolayer without cytotoxicity. Next, when FGF-21 polyplex (500 mg) was orally administered, the body weight and blood glucose levels of high-fat diet-induced (HDI) mice were decreased. As on-going works, we are also examining the expression of FGF-21 and insulin protein in the pancreas and liver, etc via biopsy of these animals. |
